grant
A Novel Drug Target for Aggressive Prostate Cancer
Organization MIAMI VA HEALTH CARE SYSTEMLocation MIAMI, UNITED STATESPosted 1 Jan 2018Deadline 31 Mar 2028
VANIHUS FederalResearch GrantFY20253-D3-Dimensional3DAI AugmentedAI assistedAI basedAI drivenAI enhancedAI integratedAI poweredAndrogen ReceptorArtificial Intelligence enhancedAssayAugmented by AIAugmented by the AIAugmented with AIAugmented with the AIBenignBinding SitesBioassayBiochemicalBiological AssayBone MetastasisBone cancer metastaticBony metastasisCancer BiologyCancer PatientCancersCastrationCell Growth in NumberCell LineCell MultiplicationCell ProliferationCell divisionCellLineCellular ProliferationClinicalClinical TrialsCombining SiteCoupledDataDevelopmentDrugsEffectivenessEvolutionExperimental GeneticsExperimental TherapiesFutureGene TranscriptionGeneralized GrowthGenerationsGenesGenetic TranscriptionGenome InstabilityGenomic InstabilityGoalsGrowthHeterogeneityHomology ModelingInvestigational TherapiesInvestigational TreatmentsKinasesL-SerineLeadLigandsLinkMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMedicationMedicinal ChemistryMessenger RNAMetastasisMetastasis to boneMetastasizeMetastatic Cancer to the BoneMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the BoneMetastatic TumorMetastatic Tumor to the BoneMetastatic malignant neoplasm to boneMitosis CheckpointMitoticMitotic CheckpointModelingMolecularMolecular ConfigurationMolecular ConformationMolecular StereochemistryNeoplasm MetastasisNeuroendocrine Prostate CancerOncogenicOsseous metastasisPDX modelPatient derived xenograftPatientsPb elementPharmaceutic ChemistryPharmaceutical ChemistryPharmaceutical PreparationsPhosphotransferase GenePhosphotransferasesPhysicsPositionPositioning AttributeProliferatingProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate malignancyProstatic ParenchymaProstatic TissueProtacProtein-Serine KinaseProtein-Serine-Threonine KinasesProtein-Threonine KinaseProteinsProteolysis targeting chimericQOLQuality of lifeRNA ExpressionReactive SiteReceptor SignalingRecurrenceRecurrentRecurrent Malignant NeoplasmRecurrent Malignant TumorResistanceRoleSecondary NeoplasmSecondary TumorSecondary cancer of boneSecondary malignancy of boneSecondary malignant neoplasm of boneSeriesSerineSerine KinaseSerine-Threonine KinasesSerine/Threonine Protein Kinase GeneSiteSkeletal metastasisSolid NeoplasmSolid TumorStrains Cell LinesStructureStructure-Activity RelationshipSurgical CastrationTestingTherapeuticThreonine KinaseTimeTissue GrowthTractionTranscriptionTransphosphorylasesTreatment EfficacyVariantVariationVeteransVeterans Health AdministrationVeterans Health AffairsVisceral metastasisXtandiadvanced prostate cancerandrogen ablation therapyandrogen blockade therapyandrogen dependentandrogen deprivation therapyandrogen deprivation treatmentandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerandrogen responsiveandrogen sensitiveantagonismantagonistartificial intelligence assistedartificial intelligence augmentedartificial intelligence basedartificial intelligence drivenartificial intelligence integratedartificial intelligence poweredbone neoplasm secondarycancer diagnosiscancer metastasiscancer recurrencecastration resistant CaPcastration resistant PCacastration resistant prostate cancerchemical structure functioncombatconformationconformationalconformational stateconformationallyconformationsconstitutive expressionconstitutive gene expressioncultured cell linedeep learning based neural networkdeep learning neural networkdeep neural netdeep neural networkdevelopmentaldrug/agentdruggable targetenhanced with AIenhanced with Artificial Intelligenceenzalutamideexperimentexperimental researchexperimental studyexperimental therapeutic agentsexperimental therapeuticsexperimentsgene networkheavy metal Pbheavy metal leadhormone refractory prostate cancerhuman diseaseinhibitorinnovateinnovationinnovativeintervention efficacykinase inhibitorknock-downknockdownmRNAmalignancymembermitosis check pointmitotic check pointmulti-taskmultidisciplinarymultitaskmutantneoplasm/cancernew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetontogenyoverexpressoverexpressionpatient derived xenograft modelpatient stratificationpre-clinicalpreclinicalpreventpreventingprostate cancer cellprostate cancer cell lineprostate cancer modelprostate cancer resistant to androgenprostate cancer treatmentprostate tumor cellprostate tumor modelproteolysis targeting chimaeraproteolysis targeting chimeraresistantresponsescreeningscreeningssimulationsmall molecular inhibitorsmall moleculesmall molecule inhibitorsocial rolestandard of carestratified patientstructure function relationshiptherapeutic efficacytherapeutic targettherapy efficacythree dimensionaltumortumor cell metastasisvirtual screeningvirtual screenings
Description preview
Prostate cancer (PC) that recurs following standard of care androgen-deprivation therapy is termed
castration-resistant prostate cancer (CRPC) and is currently incurable. CRPC is marked by reactivation of
androgen receptor (AR) signaling, eventual metastasis and, in some cases, further evolution to AR null/AR
indifferent neuroendocrine PC (NEPC).…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click